Compare Kraft Heinz Co (KHC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Sanofi SA — how do they compare? Kraft Heinz Co trades at $22.27 (market cap $26.66B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 3.6× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (7.12%). Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and Sanofi SA for 94 Days on average.
| KHC | SNY | |
|---|---|---|
Market Cap | $26.66B | $95.18B |
Volume | 31,300,109 | 2,995,646 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $52.34 |
52-Week Low | $21.21 | $39.51 |
Typical Hold Time | 129 Days | 94 Days |
Enterprise Value | $42.98B | $114.48B |
Dividend Yield | 7.12% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.48, up 2.27% on the day, with a bearish technical signal and mixed fundamentals. The stock shows a low P/E of 13.04 and P/B of 0.74, but negative net income and ROE reflect profitability challenges. Recent earnings have beaten estimates, and the company maintains a $0.40 dividend. Cash flow improved in 2025, though revenue declined to $24.94 billion. News highlights turnaround efforts, including new product launches and a halted breakup plan.
The outlook is cautious; while valuation appears cheap and dividends attract income investors, persistent negative margins and high debt pose risks. Analyst consensus is mixed with a $24.50 price target, but bearish sentiment and competitive pressures suggest limited near-term upside. Investors should weigh the dividend yield against execution risks in the consumer goods sector.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
